Mutations in PMM2 that cause congenital disorders of glycosylation, type Ia (CDG-Ia)

Human Mutation

Volumn 16, Issue 5, 2000, Pages 386-394

  Matthijs, G ^a   Schollen, E ^a   Bjursell, C ^b   Erlandson, A ^b   Freeze, H ^c   Imtiaz, F ^d   Kjaergaard, S ^e   Martinsson, T ^b   Schwartz, M ^e   Seta, N ^f   Vuillaumier Barrot, S ^f   Westphal, V ^c   Winchester, B ^d  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b University Hospitals   (Sweden)

^c BURNHAM INSTITUTE   (United States)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e Rigshospitalet   (Denmark)

^f BICHAT HOSPITAL   (France)

Author keywords

Carbohydrate deficient glycoprotein syndrome; CDG Ia; CDGS; Congenital disorders of glycosylation; Phosphomannomutase 2; PMM2, mutation analysis; Type Ia

Indexed keywords

GENE PRODUCT; PROTEIN PMM2; UNCLASSIFIED DRUG;

CONGENITAL DISORDER OF GLYCOSYLATION; CONGENITAL DISORDER OF GLYCOSYLATION TYPE 1A; GENE MUTATION; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENOTYPE; GEOGRAPHIC DISTRIBUTION; HUMAN; MAJOR CLINICAL STUDY; MISSENSE MUTATION; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; REVIEW;

ADOLESCENT; ADULT; AMINO ACID SEQUENCE; CARBOHYDRATE-DEFICIENT GLYCOPROTEIN SYNDROME; CHILD; EXONS; GENOTYPE; GLYCOSYLATION; HUMANS; INFANT; INFANT, NEWBORN; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; PHENOTYPE; PHOSPHOTRANSFERASES (PHOSPHOMUTASES); POLYMORPHISM, GENETIC;

EID: 0033736282     PISSN: 10597794     EISSN: None     Source Type: Journal    
DOI: 10.1002/1098-1004(200011)16:5<386::AID-HUMU2>3.0.CO;2-Y     Document Type: Review

References (30)

1. The catalytic domain of the P-type ATPase has the haloacid dehalogenase fold
2. Fine mapping of the gene for carbohydrate-deficient glycoprotein syndrome, type I (CDG1): Linkage disequilibrium and founder effect in Scandinavian families
3. Detailed mapping of the phosphomannomutase 2 (PMM2) gene and mutation detection enable improved analysis for Scandinavian CDG type I families
4. PMM2 mutation spectrum, including 10 novel mutations, in a large CDG Type 1A family material with focus on Scandinavian families
5. Prenatal diagnosis and the subsequent mutation analysis in a family with carbohydrate-deficient glycoprotein type I syndrome: Growing evidence to support founder effects within CDG1 populations
6. Carbohydrate-deficient glycoprotein syndrome: Beyond the screen
7. Genotypes and phenotypes of patients in the UK with carbohydrate-deficient glycoprotein syndrome type 1
8. Familial psychomotor retardation with markedly fluctuating serum proteins, FSH and GH levels, partial TBG deficiency, increased serumarylsulphatase A and increased CSF protein: A new syndrome?
9. Syndrome of the month: Carbohydrate-deficient glycoprotein (CDG) syndrome type I
10. Defects of N-glycan synthesis
11. The yeast SEC53 gene encodes phosphomannomutase
12. Absence of homozygosity for predominant mutations in PMM2 in Danish patients with carbohydrate-deficient glycoprotein syndrome type 1
13. Carbohydrate-deficient glycoprotein syndrome type 1A: Expression and characterisation of wild type and mutant PMM2 in E. coli
14. Missense mutations in phosphomannomutase 2 gene in two Japanese families with carbohydrate-deficient glycoprotein syndrome type 1
15. Clinical manifestations in three American adult patients with carbohydrate deficient glycoprotein syndrome
16. CDG-1 - A recently discovered hereditary metabolic disease. Multiple organ manifestations, incidence 1/80,000, difficult to treat
17. PMM (PMM1), the human homologue of SEC53 or yeast phosphomannomutase, is localized on chromosome 22q13
18. Mutations in PMM2, a phosphomannomutase gene on chromosome 16p13, in carbohydrate-deficient glycoprotein type I syndrome (Jaeken syndrome)
19. Lack of homozygotes for the most frequent disease allele in carbohydrate-deficient glycoprotein syndrome type 1A
20. Missense mutations in the phosphomannomutase 2 gene of two Japanese siblings with carbohydrate-deficient glycoprotein syndrome type I
21. Carbohydrate-deficient glycoprotein syndromes become congenital disorders of glycosylation: An updated nomenclature for CDG
22. Carbohydrate-deficient glycoprotein syndromes become congenital disorders of glycosylation: An updated nomenclature for CDG
23. Kinetic properties and tissular distribution of mammalian phosphomannomutase isozymes
24. Effect of mutations found in patients with carbohydrate-deficient glycoprotein syndrome Type IA on the activity of phosphomannomutase 2
25. Comparative analysis of the phosphomannomutase genes PMM1, PMM2 and PMM2ψ: The sequence variation in the processed pseudogene is a reflection of the mutations found in the functional gene
26. Lack of Hardy-Weinberg equilibrium for the most prevalent PMM2 mutation in CDG-Ia (congenital disorders of glycosylation type Ia)
27. Denaturating high performance liquid chromatography (DHPLC) for PMM2 mutation screening in CDG type 1A patients
28. Characterization of the 415G>A (E139K) PMM2 mutation in carbohydrate-deficient glycoprotein syndrome type Ia disrupting a splicing enhancer resulting in exon 5 skipping
29. Identification of a IVS4-58delATG polymorphism in the human phosphomannomutase 2 (PMM2) gene
30. Identification of four novel PMM2 mutations in congenital disorders of glycosylation (CDG) Ia French patients